bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 2 from Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy
Authors: Wheeler Heather E. , Gamazon Eric R. , Wing Claudia , Njiaju Uchenna O. , Njoku Chidiamara , Baldwin Robert Michael , Owzar Kouros , Jiang Chen , Watson Dorothy , Shterev Ivo , Kubo Michiaki , Zembutsu Hitoshi , Winer Eric P. , Hudis Clifford A. , Shulman Lawrence N. , Nakamura Yusuke , Ratain Mark J. , Kroetz Deanna L. , Cox Nancy J. , Dolan Mary Eileen
Published: April 2023

PDF file - 1866K, The 11 overlap SNPs within genes associated with both patient paclitaxel-induced sensory peripheral neuropathy (P < 0.05) and LCL paclitaxel-induced cytotoxicity (P < 0.001). The Kaplan Meier plots show the probability of the first instance of Grade 2 or greater neuropathy (event) as a function of cumulative paclitaxel dose. The boxplots show the survival of LCLs treated with 12.5 nM paclitaxel (adjusted for percent CEU ancestry) versus each genotype.
Supplementary Figure 3 from MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research
Authors: Chang Wendy , Brohl Andrew S. , Patidar Rajesh , Sindiri Sivasish , Shern Jack F. , Wei Jun S. , Song Young K. , Yohe Marielle E. , Gryder Berkley , Zhang Shile , Calzone Kathleen A. , Shivaprasad Nityashree , Wen Xinyu , Badgett Thomas C. , Miettinen Markku , Hartman Kip R. , League-Pascual James C. , Trahair Toby N. , Widemann Brigitte C. , Merchant Melinda S. , Kaplan Rosandra N. , Lin Jimmy C. , Khan Javed
Published: April 2023

Using transcriptome data for expression profiling of tumors. Heatmap of transcriptome data allowing for expression profiling and clustering of diagnoses based on the 2000 most highly differentially expressed genes in comparison to the other cohort samples to validate tumor diagnosis. The diagnostic abbreviations are the same as in Figure 1 with the addition of EWLS for Ewing-like sarcoma.
Data Supplement from Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to Smoking History
Authors: Karlsson Anna , Ringnér Markus , Lauss Martin , Botling Johan , Micke Patrick , Planck Maria , Staaf Johan
Published: April 2023

Supplementary Figure S5. Principal component analysis of the TCGA and Chitale et al. transcriptional cohorts showing the variance in gene expression associated with clinicopathological factors and gene expression phenotypes.
Supplementary Figure S3 from TNF-Related Apoptosis-Inducing Ligand (TRAIL)–Armed Exosomes Deliver Proapoptotic Signals to Tumor Site
Authors: Rivoltini Licia , Chiodoni Claudia , Squarcina Paola , Tortoreto Monica , Villa Antonello , Vergani Barbara , Bürdek Maja , Botti Laura , Arioli Ivano , Cova Agata , Mauri Giorgio , Vergani Elisabetta , Bianchi Beatrice , Della Mina Pamela , Cantone Laura , Bollati Valentina , Zaffaroni Nadia , Gianni Alessandro Massimo , Colombo Mario Paolo , Huber Veronica
Published: April 2023

Supplementary Figure S3. Generation of pro-apoptotic TRAIL exosomes with other donor cells and/or other transfection tools. TRAIL expression by K562 cells transduced with AdenoTRAIL vector and pro-apoptotic activity of derived exosomes (A). TRAIL expression by CD34+ cells transduced with AdenoTRAIL vector, characterization (electronmicroscopy and Western blot) and pro-apoptotic activity of derived exosomes (B).
Supplementary Figure S2 from TNF-Related Apoptosis-Inducing Ligand (TRAIL)–Armed Exosomes Deliver Proapoptotic Signals to Tumor Site
Authors: Rivoltini Licia , Chiodoni Claudia , Squarcina Paola , Tortoreto Monica , Villa Antonello , Vergani Barbara , Bürdek Maja , Botti Laura , Arioli Ivano , Cova Agata , Mauri Giorgio , Vergani Elisabetta , Bianchi Beatrice , Della Mina Pamela , Cantone Laura , Bollati Valentina , Zaffaroni Nadia , Gianni Alessandro Massimo , Colombo Mario Paolo , Huber Veronica
Published: April 2023

Supplementary Figure S2. Homing of PKH26-labeled TRAIL exosomes. Schedule of injections (A), detection of fluorescent TRAIL exosomes by confocal microscopy in lesions (B) and of apoptotic cells in suspensions of tumors (C).
Supplementary Figure S1 from TNF-Related Apoptosis-Inducing Ligand (TRAIL)–Armed Exosomes Deliver Proapoptotic Signals to Tumor Site
Authors: Rivoltini Licia , Chiodoni Claudia , Squarcina Paola , Tortoreto Monica , Villa Antonello , Vergani Barbara , Bürdek Maja , Botti Laura , Arioli Ivano , Cova Agata , Mauri Giorgio , Vergani Elisabetta , Bianchi Beatrice , Della Mina Pamela , Cantone Laura , Bollati Valentina , Zaffaroni Nadia , Gianni Alessandro Massimo , Colombo Mario Paolo , Huber Veronica
Published: April 2023

Supplementary Figure S1. Characterization of K562 TRAIL+ cells. Viability (A), cytokine production (B) and surface molecule expression (C) of K562 TRAIL+ cells cultured in serum free conditions for exosome production. Expression of TRAIL death receptors (D) and membrane TRAIL during long-term culture (E) and large-scale expansion for exosome production (F).
Data Supplement from GSK-3β–Regulated N-Acetyltransferase 10 Is Involved in Colorectal Cancer Invasion
Authors: Zhang Hong , Hou Wei , Wang Hua-Li , Liu Hai-Jing , Jia Xin-Ying , Zheng Xing-Zheng , Zou Yong-Xin , Li Xin , Hou Lin , McNutt Michael A. , Zhang Bo
Published: April 2023

Supplementary Figure S5. Expression of GSK-3β influenced cell migration and invasion.
Supplementary Figure S2 from High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor–Positive Metastatic Breast Cancer
Authors: Alves Carla L. , Elias Daniel , Lyng Maria , Bak Martin , Kirkegaard Tove , Lykkesfeldt Anne E. , Ditzel Henrik J.
Published: April 2023

Putative upstream kinase scoring using kinase-substrate predictions of PamGene array data following specific CDK6 knockdown in parental MCF-7/S0.5 cells.
Supplementary Figure 1 from Sequential Use of the Androgen Synthesis Inhibitors Ketoconazole and Abiraterone Acetate in Castration-Resistant Prostate Cancer and the Predictive Value of Circulating Androgens
Authors: Kim Won , Zhang Li , Wilton John H. , Fetterly Gerald , Mohler James L. , Weinberg Vivian , Morse Allison , Szmulewitz Russell Z. , Friedlander Terence W. , Fong Lawrence , Lin Amy M. , Harzstark Andrea L. , Molina Arturo , Small Eric J. , Ryan Charles J.
Published: April 2023

Supplementary Figure 1. Trial schema
Supplemental figure legends and methods from HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia
Authors: Lai Tsung-Huei , Ewald Brett , Zecevic Alma , Liu Chaomei , Sulda Melanie , Papaioannou Dimitrios , Garzon Ramiro , Blachly James S. , Plunkett William , Sampath Deepa
Published: April 2023

Supplemental figure legends and methods Table 1. Combination of sapacitabine (CNDAC) and panobinostat (PS) or vorinostat (SAHA) in leukemia cell lines. Table 2. Expression levels of the miRNA induced after HDAC inhibition in OCIAML3 cells and their predicted targets within the HR repair pathway. Table 3 Characteristics of AML blasts
Supplementary Figure S4 from miR-663 Suppresses Oncogenic Function of CXCR4 in Glioblastoma
Authors: Shi Yu , Chen Cong , Yu Shi-Zhu , Liu Qing , Rao Jun , Zhang Hua-Rong , Xiao Hua-Liang , Fu Ti-Wei , Long Hua , He Zhi-Cheng , Zhou Kai , Yao Xiao-Hong , Cui You-Hong , Zhang Xia , Ping Yi-Fang , Bian Xiu-Wu
Published: April 2023

Supplementary Figure S4. The prognostic significance of miR-663 and CXCR4 in astrocytic glioma.
Supplemental Materials and Methods and figure legends from Olfactory Receptor Family 7 Subfamily C Member 1 Is a Novel Marker of Colon Cancer–Initiating Cells and Is a Potent Target of Immunotherapy
Authors: Morita Rena , Hirohashi Yoshihiko , Torigoe Toshihiko , Ito-Inoda Satoko , Takahashi Akari , Mariya Tasuku , Asanuma Hiroko , Tamura Yasuaki , Tsukahara Tomohide , Kanaseki Takayuki , Kubo Terufumi , Kutomi Goro , Mizuguchi Toru , Terui Takeshi , Ishitani Kunihiko , Hashino Satoshi , Kondo Toru , Minagawa Nozomi , Takahashi Norihiko , Taketomi Akinobu , Todo Satoru , Asaka Masahiro , Sato Noriyuki
Published: April 2023

Supplemental Materials and Methods and figure legends
Validation of EID3 expression in LPACs. from Cancer Stem-like Properties in Colorectal Cancer Cells with Low Proteasome Activity
Authors: Munakata Koji , Uemura Mamoru , Tanaka Shinji , Kawai Kenji , Kitahara Tomohiro , Miyo Masaaki , Kano Yoshihiro , Nishikawa Shinpei , Fukusumi Takahito , Takahashi Yusuke , Hata Taishi , Nishimura Junichi , Takemasa Ichiro , Mizushima Tsunekazu , Ikenaga Masakazu , Kato Takeshi , Murata Kohei , Carethers John M. , Yamamoto Hirofumi , Doki Yuichiro , Mori Masaki
Published: April 2023

EID3 was identified by microarray analysis. The expression of EID3 was confirmed by PCR and western blotting. (A) The mRNA expression of EID3 was significantly enriched in LPACs of HCT116, KM12SM and DLD1 compared to non-LPACs, except SW480 which just missed statistical significance (p=0.0555). (B) Western blotting was also performed for checking the expression of EID3 protein in LPACs and non-LPACs using EID3 antibody (Abcam, Cambridge, UK, ab124447), but the evaluation was difficult, because expression of EID3 is low in humans as per previous report (31, 32). * p<0.05.
Supplementary Table 1 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
Authors: Leary Alexandra , Evans Abigail , Johnston Stephen R.D. , A'Hern Roger , Bliss Judith M. , Sahoo Rashmita , Detre Simone , Haynes Benjamin P. , Hills Margaret , Harper-Wynne Catherine , Bundred Nigel , Coombes Gill , Smith Ian , Dowsett Mitch
Published: April 2023

Supplementary Table 1. Toxicities: incidence and National Cancer Institute (NCI) CTC grading
Supplementary Figures 1-8, Supplementary Tables 1-4 from Highly Expressed Genes in Rapidly Proliferating Tumor Cells as New Targets for Colorectal Cancer Treatment
Authors: Bazzocco Sarah , Dopeso Higinio , Carton-Garcia Fernando , Macaya Irati , Andretta Elena , Chionh Fiona , Rodrigues Paulo , Garrido Miriam , Alazzouzi Hafid , Nieto Rocio , Sanchez Alex , Schwartz Simo , Bilic Josipa , Mariadason John M. , Arango Diego
Published: April 2023

Supplementary Figures 1-8, Supplementary Tables 1-4. Supplementary Figures 1-8: S1: Cell growth as a function of the mutational status of the most frequently mutated genes in colorectal tumors; S2: Independent validation of mRNA expression levels; S3: Correlation between PPOX or GAPDH expression and rates of proliferation in primary tumors; S4: Correlation between drug sensitivity and proliferation rates of colon cancer cells; S5: Effects of acifluorfen and Na iodoacetate on the clonogenic potential of colon cancer cells and induction of apoptosis; S6: Effects of acifluorfen or Na iodoacetate treatment on the cell cycle of colon cancer cells; S7: Effects of PPOX and GAPDH inhibition on the growth of colon cancer cells; S8: Effects of GAPDH and PPOX inhibition on tumor growth using a xenograft model; Supplementary Tables 1-4: S1: Cell lines used in this study; S2: 1593 probes (1,290 unique DAVID IDs) with expression levels significantly correlated with the doubling time of a panel of 31 colorectal cancer cell lines; S3: Functional group enrichment analysis using Gene Ontology categories. Only significantly enriched categories are shown (Benjamini-Hochberg-corrected p<0.05); S4: Associations between PPOX or GAPDH levels and clinicopathological features of a cohort of 433 colorectal tumors from the TCGA.
Supplementary Figure Legend from Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60
Authors: Reinhold William C. , Sunshine Margot , Varma Sudhir , Doroshow James H. , Pommier Yves
Published: April 2023

Supplementary Figure Legend
Supplemental Video M6 from A Systematic Comparison of 18F-C-SNAT to Established Radiotracer Imaging Agents for the Detection of Tumor Response to Treatment
Authors: Witney Timothy H. , Hoehne Aileen , Reeves Robert E. , Ilovich Ohad , Namavari Mohammad , Shen Bin , Chin Frederick T. , Rao Jianghong , Gambhir Sanjiv S.
Published: April 2023

Supplemental Video M6. 18FC-SNAT uptake in drug-treated tumors
Supplemental Figure 2 from Human Anaplastic Thyroid Carcinoma Cells Are Sensitive to NK Cell–Mediated Lysis via ULBP2/5/6 and Chemoattract NK Cells
Authors: Wennerberg Erik , Pfefferle Aline , Ekblad Lars , Yoshimoto Yuya , Kremer Veronika , Kaminskyy Vitaliy O , Juhlin C Christofer , Höög Anders , Bodin Inger , Svjatoha Vitalijs , Larsson Catharina , Zedenius Jan , Wennerberg Johan , Lundqvist Andreas
Published: April 2023

Supplemental Figure 2. (A) Gating strategy for NKG2D expression on NK cells in FNA and PBMCs from an ATC patient. Lymphocytes are gated according to size (forward scatter FSC) and granularity (side scatter SSC), viability (7AAD- cells), NK cell phenotype (CD3-CD56+ cells) and NKG2D expression is plotted as a histogram where solid grey histogram represent isotype control antibody staining and open histogram represent staining with NKG2D-specific antibody. (B) Gating strategy for ULBP2/5/6 expression in FNA from an ATC patient. Tumor cells are first gated according to size (forward scatter FSC), granularity (side scatter SSC) and viability (LIVE/DEAD- cells). Granulocytes that may appear in the same FSC/SSC population are gated out by excluding the CD11c+ cells. ULBP2/5/6 expression is plotted as a histogram where solid grey histogram represents isotype control. antibody staining and open histogram represents staining with ULBP2/5/6-specific antibody. FNA = fine needle aspirate. PBMC = peripheral blood mononuclear cells.
Supplemental Video M4 from A Systematic Comparison of 18F-C-SNAT to Established Radiotracer Imaging Agents for the Detection of Tumor Response to Treatment
Authors: Witney Timothy H. , Hoehne Aileen , Reeves Robert E. , Ilovich Ohad , Namavari Mohammad , Shen Bin , Chin Frederick T. , Rao Jianghong , Gambhir Sanjiv S.
Published: April 2023

Supplemental Video M4. 18FML-10 uptake in drug-treated tumors
Supplemental Figures S1-4 and Tables 1-2 from A Systematic Comparison of 18F-C-SNAT to Established Radiotracer Imaging Agents for the Detection of Tumor Response to Treatment
Authors: Witney Timothy H. , Hoehne Aileen , Reeves Robert E. , Ilovich Ohad , Namavari Mohammad , Shen Bin , Chin Frederick T. , Rao Jianghong , Gambhir Sanjiv S.
Published: April 2023

Supplemental Figures S1-4 and Tables 1-2. Supplemental Figure S1. Mechanism of 18F-C-SNAT activation, cyclization and intracellular trapping; Supplemental Figure S2. Flow cytometric analysis of cell death in EL-4 cell mixtures; Supplemental Figure S3. Radiotracer uptake and retention in carboplatin- and vehicle-treated PC9 and A549 non small cell lung cancer cells; Supplemental Figure S4. SPECT imaging of 99mTc-Annexin V uptake in vivo; Supplemental Table 1. Ex vivo biodistribution data for selected tissues in naive and drug-treated mice 90 min after injection; Supplemental Table 2. Radiotracer tumor-to-tissue ratios in naive and drug-treated EL-4 xenografts 90 min after injection.
Supplemental Tables from Loss of SMAD4 Promotes Colorectal Cancer Progression by Accumulation of Myeloid-Derived Suppressor Cells through the CCL15–CCR1 Chemokine Axis
Authors: Inamoto Susumu , Itatani Yoshiro , Yamamoto Takamasa , Minamiguchi Sachiko , Hirai Hideyo , Iwamoto Masayoshi , Hasegawa Suguru , Taketo Makoto Mark , Sakai Yoshiharu , Kawada Kenji
Published: April 2023

Supplemental Table 1, 2 and 3. Supplemental Table 1: List of antibodies. Table 2: CCL15 expression according to Stage- and T factor-based classifications. Table 3: Tumor characteristics of another cohort of 132 patients.
supplemental legend from Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer
Authors: Farren Matthew R. , Mace Thomas A. , Geyer Susan , Mikhail Sameh , Wu Christina , Ciombor Kristen , Tahiri Sanaa , Ahn Daniel , Noonan Anne M. , Villalona-Calero Miguel , Bekaii-Saab Tanios , Lesinski Gregory B.
Published: April 2023

supplemental legend
Supplementary Figure S1 from Dysregulation of miR-212 Promotes Castration Resistance through hnRNPH1-Mediated Regulation of AR and AR-V7: Implications for Racial Disparity of Prostate Cancer
Authors: Yang Yijun , Jia Dingwu , Kim Hogyoung , Abd Elmageed Zakaria Y. , Datta Amrita , Davis Rodney , Srivastav Sudesh , Moroz Krzysztof , Crawford Byron E. , Moparty Krishnarao , Thomas Raju , Hudson Robert S. , Ambs Stefan , Abdel-Mageed Asim B.
Published: April 2023

Schematic representation of the functional genomics approach
Supplemental Figure 1 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases
Authors: Katz Steven C. , Burga Rachel A. , McCormack Elise , Wang Li Juan , Mooring Wesley , Point Gary R. , Khare Pranay D. , Thorn Mitchell , Ma Qiangzhong , Stainken Brian F. , Assanah Earle O. , Davies Robin , Espat N. Joseph , Junghans Richard P.
Published: April 2023

Supplemental Figure 1. In vitro cytotoxicity assay
Supplementary Figure S1 from A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer
Authors: Drilon Alexander , Somwar Romel , Wagner Jacob P. , Vellore Nadeem A. , Eide Christopher A. , Zabriskie Matthew S. , Arcila Maria E. , Hechtman Jaclyn F. , Wang Lu , Smith Roger S. , Kris Mark G. , Riely Gregory J. , Druker Brian J. , O'Hare Thomas , Ladanyi Marc , Davare Monika A.
Published: April 2023

Sequence alignment to reference genome reveals an acquired C6097G>A (D2033N) mutation in ROS1 after treatment with crizotinib. The MSK-IMPACT (Integrated Mutational Profiling of Actionable Targets, Illumina HiSeq 2500, 341-gene panel) platform was used for broad, hybrid-capture next-generation sequencing of (A) pre- and (B) post-crizotinib tumor tissue. Data is displayed via the Integrated Genomics Viewer (IGV). A novel acquired ROS1 D2033N mutation (c.6097G>A) was detected in the post-crizotinib treatment tumor sample but was not detected before treatment.
supplemental figure legend from Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation
Authors: Hung Amos C. , Lo Steven , Hou Ming-Feng , Lee Yi-Chen , Tsai Chun-Hao , Chen Yuan-Yin , Liu Wangta , Su Yu-Han , Lo Yi-Hsuan , Wang Chie-Hong , Wu Shiou-Chen , Hsieh Ya-Ching , Hu Stephen Chu-Sung , Tai Ming-Hong , Wang Yun-Ming , Yuan Shyng-Shiou F.
Published: April 2023

supplemental figure legend
Supplementary Table 2 and 3 from Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer
Authors: Tang Ke-Jing , Constanzo Jerfiz D. , Venkateswaran Niranjan , Melegari Margherita , Ilcheva Mariya , Morales Julio C. , Skoulidis Ferdinandos , Heymach John V. , Boothman David A. , Scaglioni Pier Paolo
Published: April 2023

Supplementary Table 2. The table shows the IC50 for FAKi PF-562, 271 for the indicated cell lines. Supplementary Table 3. The table shows the Dq, Do and Dose enhancement ratios of NSCLC cells treated as indicated. Dose enhancement ratios at LD50 and LD20 levels were calculated by direct examination of survival curves. Survival parameters (i.e., Dq and Do) were also derived from survival curves shown in Fig. 4 using the relationship, loge n = Dq/Do.
Supplementary Figure 1b from Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy
Authors: Santa-Maria Cesar A. , Blackford Amanda , Nguyen Anne T. , Skaar Todd C. , Philips Santosh , Oesterreich Steffi , Rae James M. , Desta Zeruesenay , Robarge Jason , Henry Norah Lynn , Storniolo Anna M. , Hayes Daniel F. , Blumenthal Roger S. , Ouyang Pamela , Post Wendy S. , Flockhart David A. , Stearns Vered
Published: April 2023

Supplementary Figure 1b. Manhattan plots demonstrating associations between variants in the CYP19A1 gene and absolute changes HDL-C using dominant (A) and additive (B) in letrozole treated participants taking lipid lowering medication.
Supplementary table 1 from Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer
Authors: Liu Yi-Rong , Jiang Yi-Zhou , Xu Xiao-En , Hu Xin , Yu Ke-Da , Shao Zhi-Ming
Published: April 2023

Supplementary Table 1. Selected mRNAs and lncRNAs by comparing the expression profiles in 33 paired tumor and adjacent normal tissues of triple-negative breast cancer.
supplemental figure legend from SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Authors: Hidalgo Manuel , Plaza Carlos , Musteanu Monica , Illei Peter , Brachmann Carrie B. , Heise Carla , Pierce Daniel , Lopez-Casas Pedro P. , Menendez Camino , Tabernero Josep , Romano Alfredo , Wei Xinyu , Lopez-Rios Fernando , Von Hoff Daniel D.
Published: April 2023

supplemental figure legend
Supplementary Table 4 from Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3–FOXO1-Positive Alveolar Rhabdomyosarcoma
Authors: Kephart Julie J.G. , Tiller Rosanne G.J. , Crose Lisa E.S. , Slemmons Katherine K. , Chen Po-Han , Hinson Ashley R. , Bentley Rex C. , Chi Jen-Tsan Ashley , Linardic Corinne M.
Published: April 2023

Supplementary Table 4: Wnt-related genes consistently altered by SFRP3 suppression.
Table S2 from SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Authors: Hidalgo Manuel , Plaza Carlos , Musteanu Monica , Illei Peter , Brachmann Carrie B. , Heise Carla , Pierce Daniel , Lopez-Casas Pedro P. , Menendez Camino , Tabernero Josep , Romano Alfredo , Wei Xinyu , Lopez-Rios Fernando , Von Hoff Daniel D.
Published: April 2023

Table S2. Baseline Characteristics in the Tumor SPARC-Evaluable Population
Supplementary Table 3 from Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3–FOXO1-Positive Alveolar Rhabdomyosarcoma
Authors: Kephart Julie J.G. , Tiller Rosanne G.J. , Crose Lisa E.S. , Slemmons Katherine K. , Chen Po-Han , Hinson Ashley R. , Bentley Rex C. , Chi Jen-Tsan Ashley , Linardic Corinne M.
Published: April 2023

Supplementary Table 3. The GO enrichment of the induced and repressed probesets.
Sup. Fig. 1- MELK SAGE analysis from Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer
Authors: Speers Corey , Zhao Shuang G. , Kothari Vishal , Santola Alyssa , Liu Meilan , Wilder-Romans Kari , Evans Joseph , Batra Nidhi , Bartelink Harry , Hayes Daniel F. , Lawrence Theodore S. , Brown Powel H. , Pierce Lori J. , Feng Felix Y.
Published: April 2023

MELK expression (by SAGE) in all normal and cancerous human tissues
Supplemental Figure 1 from Prognostic Utility of Molecular Factors by Age at Diagnosis of Colorectal Cancer
Authors: McCleary Nadine J. , Sato Kaori , Nishihara Reiko , Inamura Kentaro , Morikawa Teppei , Zhang Xuehong , Wu Kana , Yamauchi Mai , Kim Sun A. , Sukawa Yasutaka , Mima Kosuke , Qian Zhi Rong , Fuchs Charles S. , Ogino Shuji , Meyerhardt Jeffrey A.
Published: April 2023

Supplemental Figure 1. Restricted cubic spline plot of CRC-specific and overall survival at 5 years by CTNNB1 status
Supplemental Figure 3b from PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance
Authors: Stern Howard M. , Gardner Humphrey , Burzykowski Tomasz , Elatre Wafaa , O'Brien Carol , Lackner Mark R. , Pestano Gary A. , Santiago Angela , Villalobos Ivonne , Eiermann Wolfgang , Pienkowski Tadeusz , Martin Miguel , Robert Nicholas , Crown John , Nuciforo Paolo , Bee Valerie , Mackey John , Slamon Dennis J. , Press Michael F.
Published: April 2023

Supplemental Figure 3b. Comparison of western immunoblot results and PTEN IHC in CAL-51, MDA-MB-451, HCC-1954, ZR-75-1, MCF7, CAL-120, and BT474 human breast cancer cell lines.
Supplemental Figure 1 from Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression
Authors: Ory Benjamin , Baud'huin Marc , Verrecchia Franck , Royer Bénédicte Brounais-Le , Quillard Thibaut , Amiaud Jérôme , Battaglia Séverine , Heymann Dominique , Redini Francoise , Lamoureux Francois
Published: April 2023

Supp. Figure 1. HSP90 messenger RNA level is overexpressd in osteosarcoma patients.
Supplementary Figure S4 from Trabectedin Efficacy in Ewing Sarcoma Is Greatly Increased by Combination with Anti-IGF Signaling Agents
Authors: Amaral Ana Teresa , Garofalo Cecilia , Frapolli Roberta , Manara Maria Cristina , Mancarella Caterina , Uboldi Sarah , Giandomenico Silvana Di , Ordóñez Jose Luis , Sevillano Victoria , Malaguarnera Roberta , Picci Piero , Hassan A. Bass , Alava Enrique De , D'Incalci Maurizio , Scotlandi Katia
Published: April 2023

Supplementary Figure S4. Trabectedin activity on neural differentiation in EWS.
Supplementary figures S1-7 from LOXL2 Is Highly Expressed in Cancer-Associated Fibroblasts and Associates to Poor Colon Cancer Survival
Authors: Torres Sofía , Garcia-Palmero Irene , Herrera Mercedes , Bartolomé Rubén A. , Peña Cristina , Fernandez-Aceñero M. Jesús , Padilla Guillermo , Peláez-García Alberto , Lopez-Lucendo María , Rodriguez-Merlo Rufo , de Herreros Antonio García , Bonilla Félix , Casal J. Ignacio
Published: April 2023

Supplementary figures S1-7. Figure S1. Characterization of fibroblasts isolated from patients with colon cancer. Figure S2. Proteins identified and quantified in both replicates of iTRAQ. Figure S3. Major signaling pathways affected by fibroblast activation. Figure S4 Expression of stromal biomarkers in tissues of colorectal cancer patients using HPA. Figure S5. Prognostic value of individual CAFs markers for overall survival according to GSE17538 dataset. Figure S6. Prognostic value of individual CAFs markers for disease-free survival according to GSE17538 in patients at stages I-III. Figure S7. Nuclear staining of LOXL2 in the stroma of human colon cancer
Supplementary Table S1 from LOXL2 Is Highly Expressed in Cancer-Associated Fibroblasts and Associates to Poor Colon Cancer Survival
Authors: Torres Sofía , Garcia-Palmero Irene , Herrera Mercedes , Bartolomé Rubén A. , Peña Cristina , Fernandez-Aceñero M. Jesús , Padilla Guillermo , Peláez-García Alberto , Lopez-Lucendo María , Rodriguez-Merlo Rufo , de Herreros Antonio García , Bonilla Félix , Casal J. Ignacio
Published: April 2023

Supplementary Table S1A: Clinical characteristics of patients studied for CAFs proteomic analysis. Supplementary Table S1B: Clinical data of colon cancer samples used for validation qPCR analysis. Supplementary Table S1C: Clinical data of colon cancer samples used for validation by immunohistochemistry
supplemental figure legend from Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer
Authors: Janni Wolfgang J. , Rack Brigitte , Terstappen Leon W.M.M. , Pierga Jean-Yves , Taran Florin-Andrei , Fehm Tanja , Hall Carolyn , de Groot Marco R. , Bidard François-Clement , Friedl Thomas W.P. , Fasching Peter A. , Brucker Sara Y. , Pantel Klaus , Lucci Anthony
Published: April 2023

supplemental figure legend
Supplemental Data 13 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
Authors: Lambertz Irina , Kumps Candy , Claeys Shana , Lindner Sven , Beckers Anneleen , Janssens Els , Carter Daniel R. , Cazes Alex , Cheung Belamy B. , De Mariano Marilena , De Bondt An , De Brouwer Sara , Delattre Olivier , Gibbons Jay , Janoueix-Lerosey Isabelle , Laureys Geneviève , Liang Chris , Marchall Glenn M. , Porcu Michael , Takita Junko , Trujillo David Camacho , Van Den Wyngaert Ilse , Van Roy Nadine , Van Goethem Alan , Van Maerken Tom , Zabrocki Piotr , Cools Jan , Schulte Johannes H. , Vialard Jorge , Speleman Frank , De Preter Katleen
Published: April 2023

Supplemental data 13: Summary of Gene Set Enrichment analysis results obtained on expression profiling data of CLB-Â­â€�GA on different time points (10' - 30'- 60' - 2h - 4h - 6h) after pharmacological inhibition using TAE-Â­â€�684.
Supplementary Table and Figure Legends from Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Authors: Arena Sabrina , Bellosillo Beatriz , Siravegna Giulia , Martínez Alejandro , Cañadas Israel , Lazzari Luca , Ferruz Noelia , Russo Mariangela , Misale Sandra , González Iria , Iglesias Mar , Gavilan Elena , Corti Giorgio , Hobor Sebastijan , Crisafulli Giovanni , Salido Marta , Sánchez Juan , Dalmases Alba , Bellmunt Joaquim , De Fabritiis Gianni , Rovira Ana , Di Nicolantonio Federica , Albanell Joan , Bardelli Alberto , Montagut Clara
Published: April 2023

The file contains Supplementary Table and Figure Legends
Supplemental Figure 3 from AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma
Authors: Brand Toni M. , Iida Mari , Stein Andrew P. , Corrigan Kelsey L. , Braverman Cara M. , Coan John P. , Pearson Hannah E. , Bahrar Harsh , Fowler Tyler L. , Bednarz Bryan P. , Saha Sandeep , Yang David , Gill Parkash S. , Lingen Mark W. , Saloura Vassiliki , Villaflor Victoria M. , Salgia Ravi , Kimple Randall J. , Wheeler Deric L.
Published: April 2023

Supplemental Figure 3. Genetic ablation of AXL enhances HNSCC cell line response to cisplatin, cetuximab, and radiation
Supplementary Figure 5 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
Authors: Mangsbo Sara M. , Broos Sissela , Fletcher Erika , Veitonmäki Niina , Furebring Christina , Dahlén Eva , Norlén Per , Lindstedt Malin , Tötterman Thomas H. , Ellmark Peter
Published: April 2023

Supplementary Figure 5. hCD40tg mice with one tumor on each flank were treated peritumorally in the tumor on the right flank. Tumor volumes of individual untreated tumors (red) and treated tumors (black) are displayed.
Supplementary Table 1 and 2 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
Authors: Pham Christina D. , Flores Catherine , Yang Changlin , Pinheiro Elaine M. , Yearley Jennifer H. , Sayour Elias J. , Pei Yanxin , Moore Colin , McLendon Roger E. , Huang Jianping , Sampson John H. , Wechsler-Reya Robert , Mitchell Duane A.
Published: April 2023

Supplementary Table 1:Tumors maintained expression of subgroup genes previously identified as unique to corresponding human MB subtypes, SHH and Group 3 tumors, respectively. Supplementary Table 2: Flow cytometric antibody panel.
Supplementary Table S4 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo
Authors: Herman Sarah E.M. , Mustafa Rashida Z. , Jones Jade , Wong Deanna H. , Farooqui Mohammed , Wiestner Adrian
Published: April 2023

Supplementary Table S4: % of CLL cells of PBMCs
Supplementary Figure S4 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo
Authors: Herman Sarah E.M. , Mustafa Rashida Z. , Jones Jade , Wong Deanna H. , Farooqui Mohammed , Wiestner Adrian
Published: April 2023

Supplementary Figure S4: Effect of anti-CD18 antibody treatment on adhesion to fibronectin.
Supplementary Figure 1 from The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28–Costimulated T Cells Prepared for Adoptive Therapy
Authors: Zsiros Emese , Duttagupta Priyanka , Dangaj Denarda , Li Hongzhe , Frank Renee , Garrabrant Thomas , Hagemann Ian S. , Levine Bruce L. , June Carl H. , Zhang Lin , Wang Ena , Marincola Francesco M. , Bedognetti Davide , Powell Daniel J. , Tanyi Janos , Feldman Michael D. , Kandalaft Lana E. , Coukos George
Published: April 2023

Supplementary Figure 1. Flow cytometry analysis of vaccine-primed and CD3/CD28 costimulated T cells after chemokine-induced migration.
Supplemental Figure S4 from 18F-FAZA PET Imaging Response Tracks the Reoxygenation of Tumors in Mice upon Treatment with the Mitochondrial Complex I Inhibitor BAY 87-2243
Authors: Chang Edwin , Liu Hongguang , Unterschemmann Kerstin , Ellinghaus Peter , Liu Shuanglong , Gekeler Volker , Cheng Zhen , Berndorff Dietmar , Gambhir Sanjiv S.
Published: April 2023

Supplemental Figure S4. Chemical Structure of 18F-fluoroazomycin arabinoside (18F-FAZA). Nucleoside analog contains nitroimidazole ring in α-position of arabinose ring.
supplementary legend from Vaccine-Induced Tumor Necrosis Factor–Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death
Authors: van der Sluis Tetje C. , van Duikeren Suzanne , Huppelschoten Suzanna , Jordanova Ekaterina S. , Beyranvand Nejad Elham , Sloots Arjen , Boon Louis , Smit Vincent T.H.B.M. , Welters Marij J.P. , Ossendorp Ferry , van de Water Bob , Arens Ramon , van der Burg Sjoerd H. , Melief Cornelis J.M.
Published: April 2023

supplementary legend
Supplemental figure 1 from Vaccine-Induced Tumor Necrosis Factor–Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death
Authors: van der Sluis Tetje C. , van Duikeren Suzanne , Huppelschoten Suzanna , Jordanova Ekaterina S. , Beyranvand Nejad Elham , Sloots Arjen , Boon Louis , Smit Vincent T.H.B.M. , Welters Marij J.P. , Ossendorp Ferry , van de Water Bob , Arens Ramon , van der Burg Sjoerd H. , Melief Cornelis J.M.
Published: April 2023

Supplemental figure 1) Peptide vaccination synergizes with cisplatin, which allows lowering of the cisplatin dose.
Supplementary Table Set S11-S18 from Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
Authors: Burstein Matthew D. , Tsimelzon Anna , Poage Graham M. , Covington Kyle R. , Contreras Alejandro , Fuqua Suzanne A.W. , Savage Michelle I , Osborne C. Kent , Hilsenbeck Susan G. , Chang Jenny C. , Mills Gordon B. , Lau Ching C. , Brown Powel H.
Published: April 2023

Table S11. 80 Gene Signature for NMF Cluster 1 (LAR). Table S12. 80 Gene Signature for NMF Cluster 2 (MES). Table S13. 80 Gene Signature for NMF Cluster 3 (BLIS). Table S14. 80 Gene Signature for NMF Cluster 4 (BLIA). Table S15. Assignment of Discovery Set Clusters by Discovery Set Centroids and Comparison to Discovery Set NMF. Table S16. Assignment of Validation Set Clusters by Discovery Set Centroids and Comparison to Validation Set NMF. Table S17. Description of Publically Available Data Sets, with IHC Data for ER/PR/HER2, Downloaded from Gene Omnibus Employed in 'External Set'. Table S18. Assignment of External Set Clusters by Discovery Set Centroids
Supplementary Table 1 from DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas
Authors: Malouf Gabriel G. , Su Xiaoping , Zhang Jianping , Creighton Chad J. , Ho Thai H. , Lu Yue , Raynal Noël J.-M. , Karam Jose A. , Tamboli Pheroze , Allanick Frederick , Mouawad Roger , Spano Jean-Philippe , Khayat David , Wood Christopher G. , Jelinek Jaroslav , Tannir Nizar M.
Published: April 2023

List of DNA methylation levels for each CpG sites detected by DREAM in the 2 normal kidneys and the 22 renal cell carcinomas samples. Each column represents one sample and each raw one CpG site with the relative annotations (coordinates, CpG islands or not, distance from transcription start site (TSS). The coordinates of each CpG sites are provided according to Hg18 version of the Human Genome.
Supplemental Figure 1 from Defects in the Fanconi Anemia Pathway in Head and Neck Cancer Cells Stimulate Tumor Cell Invasion through DNA-PK and Rac1 Signaling
Authors: Romick-Rosendale Lindsey E. , Hoskins Elizabeth E. , Privette Vinnedge Lisa M. , Foglesong Grant D. , Brusadelli Marion G. , Potter S. Steven , Komurov Kakajan , Brugmann Samantha A. , Lambert Paul F. , Kimple Randall J. , Virts Elizabeth L. , Hanenberg Helmut , Gillison Maura L. , Wells Susanne I.
Published: April 2023

Generation and characterization of FA-deficient (HPV positive and HPV negative) HNSCC cell models.
Supplementary Figure S4 from Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas
Authors: Tsai Harrison , Morais Carlos L. , Alshalalfa Mohammed , Tan Hsueh-Li , Haddad Zaid , Hicks Jessica , Gupta Nilesh , Epstein Jonathan I. , Netto George J. , Isaacs William B. , Luo Jun , Mehra Rohit , Vessella Robert L. , Karnes R. Jeffrey , Schaeffer Edward M. , Davicioni Elai , De Marzo Angelo M. , Lotan Tamara L.
Published: April 2023

Supplementary Figure S4: A high ratio of CDKN2A/CCND1 is associated with shorter interval to development of metastasis among high risk surgically treated men receiving adjuvant androgen deprivation therapy (ADT).
Supplementary Data 1 - 7 from Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma
Authors: Omuro Antonio , Beal Kathryn , Gutin Philip , Karimi Sasan , Correa Denise D. , Kaley Thomas J. , DeAngelis Lisa M. , Chan Timothy A. , Gavrilovic Igor T. , Nolan Craig , Hormigo Adilia , Lassman Andrew B. , Mellinghoff Ingo , Grommes Christian , Reiner Anne S. , Panageas Katherine S. , Baser Raymond E. , Tabar Viviane , Pentsova Elena , Sanchez Juan , Barradas-Panchal Renata , Zhang Jianan , Faivre Geraldine , Brennan Cameron W. , Abrey Lauren E. , Huse Jason T.
Published: April 2023

Supplementary Data 1 ELIGIBILITY CRITERIA. Supplementary Data 2 HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY PLANNING. Supplementary Data 3 MRI ACQUISITION PARAMETERS AND PROCESSING. Supplementary Data 4 Nanostring-based Tissue Correlates Methods. Supplementary Data 5 Number of patients experiencing Grades 3-5 treatment-related toxicities. Supplementary Data 6 Univariate analysis of DSC MR perfusion and diffusion MRI. Supplementary Data 7 NEUROPSYCHOLOGICAL TEST Z-SCORES, QUALITY OF LIFE, DEPRESSION AND FATIGUE SCORES OVER TIME.
Supplementary Information from Gas6/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing β-Catenin
Authors: Jin Yanli , Nie Danian , Li Juan , Du Xin , Lu Yuhong , Li Yangqiu , Liu Chang , Zhou Jingfeng , Pan Jingxuan
Published: April 2023

Supplementary Information
Supplementary Figure S8 from Gas6/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing β-Catenin
Authors: Jin Yanli , Nie Danian , Li Juan , Du Xin , Lu Yuhong , Li Yangqiu , Liu Chang , Zhou Jingfeng , Pan Jingxuan
Published: April 2023

Gas6/AXL ligation stabilizes β-catenin in a AKT-dependent manner in CML CD34+ cells.
Supplementary Figure S6 from Gas6/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing β-Catenin
Authors: Jin Yanli , Nie Danian , Li Juan , Du Xin , Lu Yuhong , Li Yangqiu , Liu Chang , Zhou Jingfeng , Pan Jingxuan
Published: April 2023

AXL inhibition reduces long-term engraftment of human CML CD34+ cells in NSI mice.
Supplementary data from Increased IFNγ+ T Cells Are Responsible for the Clinical Responses of Low-Dose DNA-Demethylating Agent Decitabine Antitumor Therapy
Authors: Li Xiang , Zhang Yan , Chen Meixia , Mei Qian , Liu Yang , Feng Kaichao , Jia Hejin , Dong Liang , Shi Lu , Liu Lin , Nie Jing , Han Weidong
Published: April 2023

Supplementary data
Supplemental Table 1 from Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma
Authors: Xi Liqiang , Pham Trinh Hoc-Tran , Payabyab Eden C. , Sherry Richard M. , Rosenberg Steven A. , Raffeld Mark
Published: April 2023

BRAF V600E allele frequencies for all data points
Supplementary figure legend unmarked from A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers
Authors: Karpel-Massler Georg , Horst Basil A. , Shu Chang , Chau Lily , Tsujiuchi Takashi , Bruce Jeffrey N. , Canoll Peter , Greene Lloyd A. , Angelastro James M. , Siegelin Markus D.
Published: April 2023

Supplementary figure legend unmarked
Supplementary Figure 1: CTCAE of liver tests for P1CT from The Effect of Hepatic Impairment on Outcomes in Phase I Clinical Trials in Cancer Subjects
Authors: Mansfield Aaron S. , Rudek Michelle A. , Vulih Diana , Smith Gary L. , Harris Pamela Jo , Ivy S. Percy
Published: April 2023

The peak CTCAE of liver tests for P1CT subjects are shown above. Amongst P1CT, there were higher ALT CTCAEs amongst subjects receiving hepatotoxic agents than non-toxic agents (p<0.01). No differences were seen in CTCAE grades for AST, ALK or total bilirubin based on type of agent.
Table S1A-D from Kub5-HeraRPRD1B Deficiency Promotes “BRCAness” and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers
Authors: Motea Edward A. , Fattah Farjana J. , Xiao Ling , Girard Luc , Rommel Amy , Morales Julio C. , Patidar Praveen , Zhou Yunyun , Porter Andrew , Xie Yang , Minna John D. , Boothman David A.
Published: April 2023

Loss of K-H genetic alterations
Supplemental Figure 2 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers
Authors: Van Roosbroeck Katrien , Fanini Francesca , Setoyama Tetsuro , Ivan Cristina , Rodriguez-Aguayo Cristian , Fuentes-Mattei Enrique , Xiao Lianchun , Vannini Ivan , Redis Roxana S. , D'Abundo Lucilla , Zhang Xinna , Nicoloso Milena S. , Rossi Simona , Gonzalez-Villasana Vianey , Rupaimoole Rajesha , Ferracin Manuela , Morabito Fortunato , Neri Antonino , Ruvolo Peter P. , Ruvolo Vivian R. , Pecot Chad V. , Amadori Dino , Abruzzo Lynne , Calin Steliana , Wang Xuemei , You M. James , Ferrajoli Alessandra , Orlowski Robert , Plunkett William , Lichtenberg Tara M. , Davuluri Ramana V. , Berindan-Neagoe Ioana , Negrini Massimo , Wistuba Ignacio I. , Kantarjian Hagop M. , Sood Anil K. , Lopez-Berestein Gabriel , Keating Michael J. , Fabbri Muller , Calin George A.
Published: April 2023

In vivo orthotopic lung cancer model for the role of miR-155 in chemoresistance. (A) Injection and treatment schedule for CDDP (green arrows) and anti-miR negative control (NC) or anti-miR-155 liposomal nanoparticles (red stars) for four different treatment groups: mice that were injected with A549-LVEV cells and untreated (group 1), injected with A549-LVEV cells and treated with anti-miR-NC and CDDP (group 2), injected with A549-155LV cells and treated with anti-miR-NC and CDDP (group 3), and injected with A549-155LV cells and treated with anti-miR-155 and CDDP (group 4). (B) Representative pictures of dissected mice belonging to each of the treatment groups described in panel A of this Figure. Tumor nodules are marked by dotted white circles. (C-D) Graphs of the primary tumor size (C) and aggregate mass of nodules in mediastinum (D) of the four treatment groups mentioned above. (E) In situ hybridization for miR-155 for each of the four treatment groups mentioned above. (F) Immunohistochemical analysis for Ki-67 (proliferation) and CD31 (angiogenesis), as well as the TUNEL assay (apoptosis) and TP53 immunostaining for each of the four treatment groups mentioned above.
Supplemental Figure 1 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers
Authors: Van Roosbroeck Katrien , Fanini Francesca , Setoyama Tetsuro , Ivan Cristina , Rodriguez-Aguayo Cristian , Fuentes-Mattei Enrique , Xiao Lianchun , Vannini Ivan , Redis Roxana S. , D'Abundo Lucilla , Zhang Xinna , Nicoloso Milena S. , Rossi Simona , Gonzalez-Villasana Vianey , Rupaimoole Rajesha , Ferracin Manuela , Morabito Fortunato , Neri Antonino , Ruvolo Peter P. , Ruvolo Vivian R. , Pecot Chad V. , Amadori Dino , Abruzzo Lynne , Calin Steliana , Wang Xuemei , You M. James , Ferrajoli Alessandra , Orlowski Robert , Plunkett William , Lichtenberg Tara M. , Davuluri Ramana V. , Berindan-Neagoe Ioana , Negrini Massimo , Wistuba Ignacio I. , Kantarjian Hagop M. , Sood Anil K. , Lopez-Berestein Gabriel , Keating Michael J. , Fabbri Muller , Calin George A.
Published: April 2023

Dose-response curves for MEC1 and MEC2 cells treated with fludarabine.
SI Tables from Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution
Authors: Tang Min , Zhao Rui , van de Velde Helgi , Tross Jennifer G. , Mitsiades Constantine , Viselli Suzanne , Neuwirth Rachel , Esseltine Dixie-Lee , Anderson Kenneth , Ghobrial Irene M. , San Miguel Jesús F. , Richardson Paul G. , Tomasson Michael H. , Michor Franziska
Published: April 2023

Supplementary Table S1. Summary statistics of the estimated slopes and turning points for the model fitting of the six cohorts from the three trials. Supplementary Table S2. Information on the number of data points in the pre-treatment phase, phase during administration of therapy, and posttreatment phase. Supplementary Table S3. Summary statistics of slopes and turning points for the treatment response data of the VISTA, MMY-2001, and APEX trials. Supplementary Table S4. Dependence of MM stage, prior administration of steroids, and the best-fitting model. Supplementary Table S5. Counts of death for single-phasic and 2-phasic patients as well as different sub-cohorts based on modeling parameters in the VISTA MP and VISTA VMP cohort during treatment. Supplementary Table S6. Summary statistics of the day differences between scheduled and actual visit dates for during-treatment response data for the VISTA MP and VISTA VMP cohort. Supplementary Table S7. Parameter values used for the hybrid mathematical model for all three cohorts.
Knockdown of HDAC3 promotes the transcription of exon 4-containing isoform in BIM gene. from Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer
Authors: Tanimoto Azusa , Takeuchi Shinji , Arai Sachiko , Fukuda Koji , Yamada Tadaaki , Roca Xavier , Ong S. Tiong , Yano Seiji
Published: April 2023

Western blotting (A) and BIM exon 4-containing isoform mRNA expression (B) in PC-9BIMi2-/- cells transfected with control (scramble) or three different HDAC3 specific siRNA. *, P < 0.05 versus siRNA control (scramble).
Table S5 from Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients
Authors: Sun Jie , Meng Hua , Yao Lu , Lv Meng , Bai Jian , Zhang Jianguang , Wang Lientu , Ouyang Tao , Li Jinfeng , Wang Tianfeng , Fan Zhaoqing , Fan Tie , Lin Benyao , Xie Yuntao
Published: April 2023

Germline Mutations in Cancer Susceptibility Genes
Supplementary Table S4 from Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity
Authors: Wheeler Heather E. , Gamazon Eric R. , Frisina Robert D. , Perez-Cervantes Carlos , El Charif Omar , Mapes Brandon , Fossa Sophie D. , Feldman Darren R. , Hamilton Robert J. , Vaughn David J. , Beard Clair J. , Fung Chunkit , Kollmannsberger Christian , Kim Jeri , Mushiroda Taisei , Kubo Michiaki , Ardeshir-Rouhani-Fard Shirin , Einhorn Lawrence H. , Cox Nancy J. , Dolan M. Eileen , Travis Lois B.
Published: April 2023

The Platinum Study CAO GWAS results for SNPs previously implicated in cisplatin-associated hearing loss.
Supplementary Figures 1-4, Supplementary Tables 1-4 from Immunization against HIF-1α Inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells In Vivo
Authors: Cecil Denise L. , Slota Meredith , O'Meara Megan M. , Curtis Benjamin C. , Gad Ekram , Dang Yushe , Herendeen Daniel , Rastetter Lauren , Disis Mary L.
Published: April 2023

Supplementary Table 1. Th1/Th2 for eleven epitopes derived from the HIF-1α protein; Supplementary Table 2. Number of tumorigenic implants in the Sca-1positive or Sca-1negative Population; Supplementary Table 3. Complete blood count (median and range) for the indicted immunization. n=4 mice/group; Supplementary Table 4. Serum chemistries (median and range) for the indicted immunization; Supplementary Figure 1. Sca-1positive cells exhibit several stem cell/EMT markers; Supplementary Figure 2. HIF-1α epitope-specific Th respond to naturally processed HIF-1α protein; Supplementary Figure 3. Sca-1positive cells have increased estrogen receptor-alpha (ER-α) gene expression; Supplementary Figure 4. The HIF-1α vaccine does not induce tissue toxicities.